SCHEMBL460190

SCHEMBL460190

O=C(Nc1ccc(OCc2ccccc2)cc1)N1CCC(=Cc2ccccn2)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.56
MAPT P10636 3/20 0.56
ALDH1A1 P00352 4/20 0.51
PDGFRB P09619 1/20 0.49
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LTA4H P09960 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
DHODH Q02127 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458637 0.84 MAPT (0.53) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL460006 0.80 FAAH (0.53) FAAHMAPTALDH1A1PDGFRBRAB9A
SCHEMBL4671482 0.78 FAAH (0.67) FAAHMAPTALDH1A1PDGFRBRAB9A
SCHEMBL13234930 0.78 FAAH (0.70) FAAHMAPTALDH1A1RAB9ANPC1
SCHEMBL15051927 0.77 NPY5R (0.46) MAPTALDH1A1LMNA
SCHEMBL15051079 0.77 KDM4E (0.46) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4671486 0.76 FAAH (0.67) FAAHMAPTALDH1A1PDGFRBRAB9A
SCHEMBL13234921 0.76 MAPT (0.71) FAAHMAPTALDH1A1RAB9ANPC1
SCHEMBL13234923 0.76 FAAH (0.71) FAAHMAPTALDH1A1PDGFRBRAB9A
SCHEMBL13234958 0.75 MAPT (0.71) FAAHMAPTALDH1A1PDGFRBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US claimed
EP-2615084-B1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO LTD (JP) 2016-01-06 EP disclosed
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
EP-2615084-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS Taiho Pharmaceutical Co., Ltd. (JP) 2013-07-17 EP disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 US disclosed
WO-2012033069-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS 大鵬薬品工業株式会社 (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS PTGIS, PTGS1, PTGDR FAAH 103/4885MAPT 4841/4885ALDH1A1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.